Výsledky vyhledávání - "Muriel Granier"

Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study

Autor: Diane Evrard, Clément Dumont, Michel Gatineau, Jean-Pierre Delord, Jérôme Fayette, Chantal Dreyer, Annemilaï Tijeras-Raballand, Armand de Gramont, Jean-François Delattre, Muriel Granier, Nasredine Aissat, Marie-Line Garcia-Larnicol, Khemaies Slimane, Benoist Chibaudel, Eric Raymond, Christophe Le Tourneau, Sandrine Faivre

Publikováno v: Cancers; Volume 14; Issue 18; Pages: 4509

Mammalian target of rapamycin (mTOR) regulates cellular functions by integrating intracellular signals and signals from the tumor microenvironment (TME). The PI3K-AKT-mTOR pathway is activated in 70% of head and neck squamous cell carcinoma (HNSCC) a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16a30102c640dcdf206499f86eb19370

Zobrazit plný text záznamu

Plný text ve formátu HTML

ALL-049 A Phase 1/2 Study to Evaluate Ponatinib With Chemotherapy in Pediatric Patients With Relapsed/Resistant/Intolerant Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia or With T315I Mutation

Autor: Lia Gore, Mignon Loh, Ching-Hon Pui, Yousif Matloub, Michael J. Hanley, Jichang Du, Meliessa Hennessy, Muriel Granier, Andrea Biondi, Lewis Silverman

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S190-S191

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6b138a1a67bb24e1620c644758f67722
https://doi.org/10.1016/s2152-2650(22)01176-4

Zobrazit plný text záznamu

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia

Tyrosine kinase inhibitors have improved survival for patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). However, prognosis for old or unfit patients remains poor. In the INCB84344-201 (formerly GIMEMA LAL 1811

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::532a7ef6c6f327838c21185db5ce9234
http://hdl.handle.net/11567/1078678

Zobrazit plný text záznamu

Poster: ALL-049 A Phase 1/2 Study to Evaluate Ponatinib With Chemotherapy in Pediatric Patients With Relapsed/Resistant/Intolerant Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia or With T315I Mutation

Autor: Lia Gore, Mignon Loh, Ching-Hon Pui, Yousif Matloub, Michael J. Hanley, Jichang Du, Meliessa Hennessy, Muriel Granier, Andrea Biondi, Lewis Silverman

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S123

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ca0b009c157de00f41a924bc10ef78d
https://doi.org/10.1016/s2152-2650(22)00733-9

Zobrazit plný text záznamu

ALL-167: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Relapsed, Resistant, or Intolerant Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) or Have the T315I Mutation

Autor: Lewis B. Silverman, Mignon L. Loh, Yousif Matloub, Michael J. Hanley, Muriel Granier, Lia Gore, Jichang Du, Meliessa Hennessy, Andrea Biondi, Ching-Hon Pui

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S271-S272

Context: Ph+ ALL is associated with improved outcomes when tyrosine kinase inhibitors (TKIs) are added to chemotherapy, with 5-year event-free survival (EFS) and overall survival (OS) for newly diagnosed patients of 60% and 86%, respectively. Ponatin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::96d283d42e8d2a601676992228b96baf
https://doi.org/10.1016/s2152-2650(21)01656-6

Zobrazit plný text záznamu

Poster: ALL-167: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Relapsed, Resistant, or Intolerant Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) or Have the T315I Mutation

Autor: Lia Gore, Mignon Loh, Ching-Hon Pui, Michael J. Hanley, Jichang Du, Yousif Matloub, Meliessa Hennessy, Muriel Granier, Andrea Biondi, Lewis Silverman

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S209

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::126c9ff4bf37367ba5f51b3f956122af
https://doi.org/10.1016/s2152-2650(21)01310-0

Zobrazit plný text záznamu

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Autor: Chin-Hon Pui, Lewis B. Silverman, Vickie Lu, Michael J. Hanley, Muriel Granier, Lia Gore, Mignon L. Loh, E. Jane Leonard, Andrea Biondi, Yousif Matloub

Publikováno v: Blood. 136:47-47

Introduction: Ph+ ALL accounts for 3-5% of pediatric ALL and is associated with improved outcomes when tyrosine kinase inhibitors (TKIs) are added to chemotherapy, with 5-year event-free survival (EFS) and overall survival (OS) of 58-60% and 70-86%,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ce328335fb8463e449754d7dd334b19
https://doi.org/10.1182/blood-2020-134724

Zobrazit plný text záznamu

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Autor: Hui-Ling Zhen, Albert Assad, Muriel Granier, Hagop M. Kantarjian, Giovanni Barosi, Alessandro M. Vannucchi, Elisabetta Gattoni, Elisa Rumi, Alessandro Rambaldi, Tiziano Barbui, Francesco Passamonti, Srdan Verstovsek, Mario Cazzola, Lisa Pieri

To the editor: Essential thrombocythemia (ET) is a Philadelphia chromosome–negative myeloproliferative neoplasm (MPN) characterized by persistent thrombocytosis, excessive bone marrow megakaryocyte proliferation, and normal erythrocyte mass.[1][1]

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ba351341db94978feaaca5da961e31e
https://europepmc.org/articles/PMC5639482/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání